GREENWICH LIFESCIENCES, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $310.66K, a 88.09% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $9.03M, a 1733.77% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $3.21M, a 171.55% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $2.61M, a 877.82% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for fiscal 2025 was $11.85M, a 534.23% increase from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for fiscal 2024 was $1.87M.
- GREENWICH LIFESCIENCES, INC. stock issued during period, value, new issues for fiscal 2020 was $6.21M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $310.66K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $9.03M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $11.85M 10-K · filed 2026-06-01 | |
| 2025-09-30 | $3.21M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $2.61M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $492.42K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $1.87M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $1.18M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $266.74K 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $299.12K 10-Q · filed 2025-11-14 | |
| 2020-12-31 | $6.21M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $6.21M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |